| ORIGINAL ARTICLES |
|
|
|
|
|
Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress |
| Lingli Ding1, Zhao Gao2, Siluo Wu1, Chen Chen3, Yamei Liu3, Min Wang1, Yage Zhang1, Ling Li1, Hong Zou4, Guoping Zhao5,6,7,8,9,10, Shengnan Qin11, Liangliang Xu1 |
1. Key Laboratory of Orthopaedics and Traumatology, Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China;
2. Er Sha Sports Training Center of Guangdong Province, Guangzhou, China;
3. School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China;
4. Engineering Laboratory for Nutrition, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China;
5. Master Lab for Innovative Application of Nature Products, National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China;
6. CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China;
7. CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China;
8. Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China;
9. State Key Laboratory of Genetic Engineering, Department of Microbiology and Immunology, School of Life Sciences, Fudan University, Shanghai, China;
10. Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China;
11. Department of Orthopaedics, Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, China |
|
|
|
|
Abstract Osteoporosis (OP), a systemic and chronic bone disease, is distinguished by low bone mass and destruction of bone microarchitecture. Ginsenoside Compound-K (CK), one of the metabolites of ginsenoside Rb1, has anti-aging, anti-inflammatory, anti-cancer, and hypolipidemic activities. We have demonstrated CK could promote osteogenesis and fracture healing in our previous study. However, the contribution of CK to osteoporosis has not been examined. In the present study, we investigated the effect of CK on osteoclastogenesis and ovariectomy (OVX)-induced osteoporosis. The results showed that CK inhibited receptor activator for nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation and reactive oxygen species (ROS) activity by inhibiting the phosphorylation of NF-κB p65 and oxidative stress in RAW264.7 cells. In addition, we also demonstrated that CK could inhibit bone resorption using bone marrow-derived macrophages. Furthermore, we demonstrated that CK attenuated bone loss by suppressing the activity of osteoclast and alleviating oxidative stress in vivo. Taken together, these results showed CK could inhibit osteoclastogenesis and prevent OVX-induced bone loss by inhibiting NF-κB signaling pathway.
|
| Keywords
Ginsenoside CK
NF-κB signaling pathway
Osteoporosis
Oxidative stress
|
| Fund:This work is supported by the grant from National Natural Science Foundation of China (81871778), Guangdong Provincial Science and Technology Collaborative Innovation Center for Sport Science (2019B110210004), and the key project of Sport Research Foundation of Guangdong Province (GDSS2022M005). |
|
Corresponding Authors:
Guoping Zhao,E-mail:gpzhao@sibs.ac.cn;Shengnan Qin,E-mail:qinqinsn@163.com;Liangliang Xu,E-mail:xull-2016@gzucm.edu.cn
E-mail: qiqin1990@163.com;gpzhao@sibs.ac.cn;qinqinsn@163.com;xull-2016@gzucm.edu.cn
|
|
Issue Date: 26 December 2023
|
|
|
| [1] |
Weitzmann MN, Ofotokun I. Physiological and pathophysiological bone turnover—role of the immune system. Nat Rev Endocrinol. 2016;12(9):518-32.
|
| [2] |
Fischer V, Haffner-Luntzer M. Interaction between bone and immune cells: implications for postmenopausal osteoporosis. Semin Cell Dev Biol. 2022;123:14-21.
|
| [3] |
Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab. 2010;21(6):369-74.
|
| [4] |
Juranek I, Bezek S. Controversy of free radical hypothesis: reactive oxygen species—cause or consequence of tissue injury? Gen Physiol Biophys. 2005;24(3):263-78.
|
| [5] |
Liu AL, Zhang ZM, Zhu BF, Liao ZH, Liu Z. Metallothionein protects bone marrow stromal cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. Cell Biol Int. 2004;28(12):905-11.
|
| [6] |
Suda N, Morita I, Kuroda T, Murota S. Participation of oxidative stress in the process of osteoclast differentiation. Biochim Biophys Acta. 1993;1157(3):318-23.
|
| [7] |
Chen K, Jiao J, Xue J, Chen T, Hou Y, et al. Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway. Oncol Rep. 2020;43(3):886-96.
|
| [8] |
Chen X, Li H, Yang Q, Lan X, Wang J, et al. Ginsenoside compound K ameliorates Alzheimer’s disease in HT22 cells by adjusting energy metabolism. Mol Biol Rep. 2019;46(5):5323-32.
|
| [9] |
Zhang J, Ma X, Fan D. Ginsenoside CK ameliorates hepatic lipid accumulation via activating the LKB1/AMPK pathway in vitro and in vivo. Food Funct. 2022;13(3):1153-67.
|
| [10] |
Chen J, Si M, Wang Y, Liu L, Zhang Y, et al. Ginsenoside metabolite compound K exerts anti-inflammatory and analgesic effects via downregulating COX2. Inflammopharmacology. 2019;27(1):157-66.
|
| [11] |
Tang M, Xie X, Yang Y, Li F. Ginsenoside compound K- a potential drug for rheumatoid arthritis. Pharmacol Res. 2021;166: 105498.
|
| [12] |
Muthukumar T, Aravinthan A, Sharmila J, Kim NS, Kim JH. Collagen/chitosan porous bone tissue engineering composite scaffold incorporated with Ginseng compound K. Carbohydr Polym. 2016;152:566-74.
|
| [13] |
Choi YS, Kang EH, Lee EY, Gong HS, Kang HS, et al. Joint-protective effects of compound K, a major ginsenoside metabolite, in rheumatoid arthritis: in vitro evidence. Rheumatol Int. 2013;33(8):1981-90.
|
| [14] |
Zhou W, Huang H, Zhu H, Zhou P, Shi X. New metabolites from the biotransformation of ginsenoside Rb1 by Paecilomyces bainier sp. 229 and activities in inducing osteogenic differentiation by Wnt/β-catenin signaling activation. J Ginseng Res. 2018;42(2):199-207.
|
| [15] |
Ding L, Gu S, Zhou B, Wang M, Zhang Y, et al. Ginsenoside compound K enhances fracture healing via promoting osteogenesis and angiogenesis. Front Pharmacol. 2022;13: 855393.
|
| [16] |
Zhang S, Shen S, Ma P, Fan D. Biochemical targets and molecular mechanism of ginsenoside compound K in treating osteoporosis based on network pharmacology. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232213921.
|
| [17] |
Charles JF, Aliprantis AO. Osteoclasts: more than “bone eaters.” Trends Mol Med. 2014;20(8):449-59.
|
| [18] |
Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123.
|
| [19] |
Ma Y, Ran D, Zhao H, Song R, Zou H, et al. Cadmium exposure triggers osteoporosis in duck via P2X7/PI3K/AKT-mediated osteoblast and osteoclast differentiation. Sci Total Environ. 2021;750: 141638.
|
| [20] |
Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer. 2010;46(12):2187-95.
|
| [21] |
Damerau A, Gaber T, Ohrndorf S, Hoff P. JAK/STAT activation: a general mechanism for bone development, homeostasis, and regeneration. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21239004.
|
| [22] |
Han D, Gu X, Gao J, Wang Z, Liu G, et al. Chlorogenic acid promotes the Nrf2/HO-1 anti-oxidative pathway by activating p21(Waf1/Cip1) to resist dexamethasone-induced apoptosis in osteoblastic cells. Free Radic Biol Med. 2019;137:1-12.
|
| [23] |
Ma H, Wang X, Zhang W, Li H, Zhao W, et al. Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoporosis. Oxid Med Cell Longev. 2020;2020:9067610.
|
| [24] |
Xu Y, Guan J, Xu J, Chen S, Sun G. Z-Guggulsterone attenuates glucocorticoid-induced osteoporosis through activation of Nrf2/HO-1 signaling. Life Sci. 2019;224:58-66.
|
| [25] |
Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385-96.
|
| [26] |
Lin TH, Pajarinen J, Lu L, Nabeshima A, Cordova LA, et al. NF-κB as a therapeutic target in inflammatory-associated bone diseases. Adv Protein Chem Struct Biol. 2017;107:117-54.
|
| [27] |
Zhu J, Tang Y, Wu Q, Ji YC, Feng ZF, et al. HIF-1α facilitates osteocyte-mediated osteoclastogenesis by activating JAK2/STAT3 pathway in vitro. J Cell Physiol. 2019;234(11):21182-92.
|
| [28] |
Ma X, Su P, Yin C, Lin X, Wang X, et al. The roles of FoxO transcription factors in regulation of bone cells function. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21030692.
|
| [29] |
Williams GR. Thyroid hormone actions in cartilage and bone. Eur Thyroid J. 2013;2(1):3-13.
|
| [30] |
Park JH, Lee NK, Lee SY. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 2017;40(10):706-13.
|
| [31] |
Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005;208:88-105.
|
| [32] |
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175-9.
|
| [33] |
Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638-49.
|
| [34] |
Chen K, Qiu P, Yuan Y, Zheng L, He J, et al. Pseurotin A inhibits osteoclastogenesis and prevents ovariectomized-induced bone loss by suppressing reactive oxygen species. Theranostics. 2019;9(6):1634-50.
|
| [35] |
Liu Y, Wang C, Wang G, Sun Y, Deng Z, et al. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics. 2019;9(16):4648-62.
|
| [36] |
Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Jt Surg Am. 2021;103(15):1451-61.
|
| [37] |
Florczyk-Soluch U, Józefczuk E, Stępniewski J, Bukowska-Strakova K, Mendel M, et al. Various roles of heme oxygenase-1 in response of bone marrow macrophages to RANKL and in the early stage of osteoclastogenesis. Sci Rep. 2018;8(1):10797.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
